ACB (Aurora Cannabis) Risk Assessment


ACB Aurora Cannabis Inc ACB
59 GF Score
Price $2.86
GF Value $4.15
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Aurora Cannabis Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Aurora Cannabis is: High Risk: High uncertainty.

Aurora Cannabis  (NAS:ACB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Aurora Cannabis Risk Assessment Related Terms

ACB vs ZTS, UTHR: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurora Cannabis Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Aurora Cannabis's Risk Assessment falls into.


ACB
59GF Score
Aurora Cannabis Inc ACB
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aurora Cannabis (ACB) Overvalued in 2026?

Based on GuruFocus' analysis, Aurora Cannabis stock appears to be undervalued. The current stock price of $2.86 is trading 31.1% below its estimated GF Value™ of $4.15. GuruFocus considers Aurora Cannabis to be Possible Value Trap.

Key valuation signals for ACB:

  • Risk Assessment:
  • GF Value™: $4.15 vs. price of $2.86 (31.1% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurora Cannabis Business Description

Address 90B Street SW, Suite 2207, Edmonton, AB, CAN, T6X 1V8
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
59GF Score

Get the complete analysis for ACB

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.86
Price
$4.15
GF Value